Uppsala, Sweden, 29 October 2012
Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced its contribution to a key paper in the Journal of Pharmacology and Experimental Therapeutics*. As part of a collaboration with Boehringer Ingelheim, Beactica scientists provided important insights into the interactions between afatinib (BIBW 2992) and members of the ErbB receptor family. The results presented in the paper provide a mechanistic rationale for the distinct pharmacological features of the compound and explain the clinical activity seen in some patients resistant to antibody or kinase inhibitor therapy.
"There is a growing awareness in the pharmaceutical industry about the importance of interaction mechanism and kinetics for drug efficacy” said Beactica’s CEO, Dr Per Källblad. "The results show that our scientific team is at the very forefront of this exciting field.
Beactica has established relationships with five of the global top-20 pharmaceutical companies as well as a growing number of biotech companies. The collaboration with Boehringer Ingelheim is ongoing since 2008.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Solca et al.,Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB family blocker, Journal of Pharmacology and Experimental Therapeutics, 2012,343:342-350
Sign up for the Beactica newsletter to receive our latest news and updates